ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology
Nick IppolitoIn addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field. Read more
Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients
Nick IppolitoDr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients. Read more
Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations
Erin JungmeyerDuring TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment. Read more
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says
Erin JungmeyerIn a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more
In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her passion for tobacco control and the importance of open-access journals in elevating research globally. Read more
Patient Perspective: ‘Scanxiety’ Triggered by Cancer, Not Scans
Dusty DonaldsonPatient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning. Read more
TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
Nick IppolitoDuring the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more
Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
Nick IppolitoDuring TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression. Read more
Revisit all your favorite moments from #TTLC23 in our photo gallery. Read more
CodeBreaK 200 Confirms Sotorasib’s Superiority Compared to Docetaxel, Investigator Says
Erin JungmeyerIn a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC. Read more